RÉSUMÉ
The development of a new series of p38α inhibitors resulted in the identification of two clinical candidates, one of which was advanced into a phase 2 clinical study for rheumatoid arthritis. The original lead, an lck inhibitor that also potently inhibited p38α, was a screening hit from our kinase inhibitor library. This manuscript describes the optimization of the lead to p38-selective examples with good pharmacokinetic properties.
Sujet(s)
Découverte de médicament/méthodes , Mitogen-Activated Protein Kinase 14/antagonistes et inhibiteurs , Pyridones/pharmacologie , Pyridones/pharmacocinétique , Pyrimidines/pharmacologie , Pyrimidines/pharmacocinétique , Administration par voie orale , Polyarthrite rhumatoïde/traitement médicamenteux , Biodisponibilité , Lignée cellulaire , Essais cliniques comme sujet , Humains , Mitogen-Activated Protein Kinase 14/composition chimique , Modèles moléculaires , Conformation des protéines , Inhibiteurs de protéines kinases/administration et posologie , Inhibiteurs de protéines kinases/composition chimique , Inhibiteurs de protéines kinases/pharmacocinétique , Inhibiteurs de protéines kinases/pharmacologie , Pyridones/administration et posologie , Pyridones/composition chimique , Pyrimidines/administration et posologie , Pyrimidines/composition chimique , Relation structure-activité , Spécificité du substratRÉSUMÉ
This phase I, open-label, single-dose study evaluates the effects of severe renal impairment and end-stage renal disease (ESRD) requiring hemodialysis on the pharmacokinetics, safety, and tolerability of sunitinib and its primary active metabolite, SU12662. Subjects with normal renal function (creatinine clearance > 80 mL/min), severe renal impairment (creatinine clearance < 30 mL/min), and ESRD requiring hemodialysis receive a single dose of sunitinib 50 mg. Serial blood samples are collected for quantification of plasma concentrations using a validated liquid chromatography with tandem mass spectrometry assay. Safety is monitored. Twenty-four subjects complete the study. Pharmacokinetics in subjects with severe renal impairment appear similar to those with normal renal function. Plasma exposure to sunitinib and SU12662 appears lower in subjects with ESRD compared with subjects with normal renal function or severe renal impairment. Single-dose sunitinib 50 mg is well tolerated regardless of renal function. The currently approved starting dose of sunitinib 50 mg on Schedule 4/2 is expected to be appropriate for patients with renal impairment; any subsequent dose modifications should be based on patients' ability to tolerate treatment.
Sujet(s)
Indoles/effets indésirables , Indoles/pharmacocinétique , Défaillance rénale chronique/traitement médicamenteux , Défaillance rénale chronique/physiopathologie , Tests de la fonction rénale , Pyrroles/effets indésirables , Pyrroles/pharmacocinétique , Adulte , Sujet âgé , Femelle , Études de suivi , Humains , Défaillance rénale chronique/métabolisme , Mâle , Taux de clairance métabolique/effets des médicaments et des substances chimiques , Taux de clairance métabolique/physiologie , Adulte d'âge moyen , SunitinibRÉSUMÉ
A novel class of highly selective inhibitors of p38 MAP kinase was discovered from high throughput screening. The synthesis and optimization of a series of 5-amino-N-phenyl-1H-pyrazol-4-yl-3-phenylmethanones is described. An X-ray crystal structure of this series bound in the ATP binding pocket of unphosphorylated p38alpha established the presence of a unique hydrogen bond between the exocyclic amine of the inhibitor and threonine 106 which likely contributes to the selectivity for p38. The crystallographic information was used to optimize the potency and physicochemical properties of the series. The incorporation of the 2,3-dihydroxypropoxy moiety on the pyrazole scaffold resulted in a compound with excellent drug-like properties including high oral bioavailability. These efforts identified 63 (RO3201195) as an orally bioavailable and highly selective inhibitor of p38 which was selected for advancement into Phase I clinical trials.